 Andrea Griesinger
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 12 | 2023 | 169 | 3.350 |
Why?
| | Infratentorial Neoplasms | 5 | 2023 | 50 | 1.400 |
Why?
| | Brain Neoplasms | 8 | 2024 | 1022 | 1.300 |
Why?
| | Immunophenotyping | 2 | 2017 | 278 | 1.020 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 74 | 0.860 |
Why?
| | Medulloblastoma | 5 | 2022 | 177 | 0.650 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 200 | 0.650 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 20 | 0.640 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 82 | 0.620 |
Why?
| | Nuclear Proteins | 3 | 2017 | 597 | 0.560 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.560 |
Why?
| | Cerebellar Neoplasms | 4 | 2022 | 135 | 0.560 |
Why?
| | Myeloid Cells | 2 | 2015 | 128 | 0.550 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 289 | 0.530 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1059 | 0.510 |
Why?
| | NF-kappa B | 1 | 2017 | 670 | 0.470 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 189 | 0.460 |
Why?
| | Gene Expression Profiling | 8 | 2024 | 1597 | 0.450 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1167 | 0.440 |
Why?
| | Interleukin-6 | 1 | 2015 | 688 | 0.400 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1774 | 0.390 |
Why?
| | Cell Proliferation | 6 | 2019 | 2275 | 0.390 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3730 | 0.360 |
Why?
| | Cell Line, Tumor | 7 | 2018 | 2851 | 0.350 |
Why?
| | Phenotype | 3 | 2024 | 3003 | 0.350 |
Why?
| | Craniopharyngioma | 2 | 2017 | 70 | 0.270 |
Why?
| | Child | 16 | 2024 | 19129 | 0.270 |
Why?
| | Chloroquine | 2 | 2017 | 64 | 0.260 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 6 | 0.240 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 202 | 0.230 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 37 | 0.230 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 454 | 0.230 |
Why?
| | Indoles | 2 | 2017 | 316 | 0.230 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.210 |
Why?
| | Signal Transduction | 1 | 2015 | 4709 | 0.210 |
Why?
| | Autophagy | 2 | 2017 | 315 | 0.210 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 136 | 0.200 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 128 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 1974 | 0.200 |
Why?
| | Apoptosis | 4 | 2019 | 2484 | 0.190 |
Why?
| | Immunotherapy, Adoptive | 2 | 2023 | 191 | 0.190 |
Why?
| | Glioma | 1 | 2024 | 306 | 0.190 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 874 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 62 | 0.180 |
Why?
| | Cytokines | 3 | 2017 | 1900 | 0.180 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 256 | 0.180 |
Why?
| | Humans | 25 | 2024 | 118972 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2019 | 740 | 0.170 |
Why?
| | Osteomyelitis | 1 | 2020 | 110 | 0.170 |
Why?
| | Mice, SCID | 1 | 2019 | 333 | 0.170 |
Why?
| | Cohort Studies | 4 | 2018 | 5116 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 187 | 0.170 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 574 | 0.160 |
Why?
| | Cyst Fluid | 1 | 2017 | 27 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2018 | 189 | 0.160 |
Why?
| | Survival Rate | 2 | 2019 | 1720 | 0.150 |
Why?
| | Epigenesis, Genetic | 2 | 2021 | 539 | 0.150 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.140 |
Why?
| | Prognosis | 4 | 2018 | 3443 | 0.140 |
Why?
| | Histones | 1 | 2021 | 552 | 0.140 |
Why?
| | Pituitary Neoplasms | 1 | 2017 | 165 | 0.140 |
Why?
| | Microarray Analysis | 4 | 2017 | 124 | 0.140 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 320 | 0.140 |
Why?
| | Transcriptional Activation | 1 | 2017 | 348 | 0.130 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 15 | 0.130 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 19 | 0.130 |
Why?
| | Transcriptome | 4 | 2023 | 756 | 0.130 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.130 |
Why?
| | Receptor, ErbB-3 | 1 | 2015 | 42 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2017 | 671 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 356 | 0.130 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 88 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2015 | 90 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2017 | 2657 | 0.120 |
Why?
| | Mice | 5 | 2023 | 15520 | 0.120 |
Why?
| | Receptors, IgG | 1 | 2013 | 67 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 115 | 0.110 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1158 | 0.110 |
Why?
| | Astrocytoma | 1 | 2013 | 113 | 0.110 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 224 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 306 | 0.110 |
Why?
| | Monocytes | 1 | 2015 | 513 | 0.110 |
Why?
| | Central Nervous System | 1 | 2014 | 245 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2015 | 502 | 0.100 |
Why?
| | Child, Preschool | 4 | 2020 | 9491 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2015 | 569 | 0.100 |
Why?
| | Glioblastoma | 1 | 2013 | 262 | 0.100 |
Why?
| | Phosphorylation | 1 | 2015 | 1633 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 336 | 0.090 |
Why?
| | Adolescent | 4 | 2018 | 18480 | 0.090 |
Why?
| | Transcription Factors | 2 | 2017 | 1570 | 0.090 |
Why?
| | Animals | 6 | 2023 | 33381 | 0.090 |
Why?
| | Epilepsy | 1 | 2013 | 290 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4596 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2013 | 900 | 0.080 |
Why?
| | Infant | 2 | 2018 | 8293 | 0.070 |
Why?
| | Drug Synergism | 2 | 2017 | 339 | 0.060 |
Why?
| | Young Adult | 2 | 2018 | 10793 | 0.060 |
Why?
| | Male | 7 | 2020 | 57801 | 0.060 |
Why?
| | Quality of Life | 1 | 2015 | 2366 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 16 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2023 | 64 | 0.060 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 32 | 0.060 |
Why?
| | Cranial Irradiation | 1 | 2023 | 70 | 0.060 |
Why?
| | Chromosomes | 1 | 2023 | 87 | 0.060 |
Why?
| | Cell Survival | 2 | 2017 | 1047 | 0.060 |
Why?
| | Adult | 3 | 2023 | 31512 | 0.050 |
Why?
| | Brain | 1 | 2013 | 2490 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 567 | 0.050 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 176 | 0.050 |
Why?
| | Epigenomics | 1 | 2021 | 107 | 0.050 |
Why?
| | Symptom Flare Up | 1 | 2020 | 41 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 175 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2020 | 59 | 0.050 |
Why?
| | Drug Substitution | 1 | 2020 | 46 | 0.050 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 176 | 0.050 |
Why?
| | Female | 5 | 2018 | 61564 | 0.050 |
Why?
| | Survivors | 1 | 2023 | 418 | 0.050 |
Why?
| | Homozygote | 1 | 2020 | 190 | 0.050 |
Why?
| | Survival Analysis | 1 | 2023 | 1267 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 632 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1032 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 73 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 379 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 254 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 77 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2018 | 153 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| | Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 28 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 136 | 0.040 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 36 | 0.040 |
Why?
| | RNA | 1 | 2023 | 833 | 0.040 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 87 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 108 | 0.040 |
Why?
| | Benzodiazepinones | 1 | 2016 | 14 | 0.040 |
Why?
| | Genes, myc | 1 | 2016 | 46 | 0.040 |
Why?
| | Disease Progression | 1 | 2023 | 2490 | 0.040 |
Why?
| | Urea | 1 | 2016 | 77 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 314 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 667 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 106 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 21 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 271 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 649 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 74 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 842 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 499 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 922 | 0.030 |
Why?
| | Pyrazoles | 1 | 2016 | 363 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 333 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 134 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2025 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 663 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 770 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 872 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 982 | 0.030 |
Why?
| | Cell Cycle | 1 | 2014 | 550 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1194 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 565 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1346 | 0.020 |
Why?
| | Gene Expression | 1 | 2015 | 1489 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1390 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 9000 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2015 | 5255 | 0.020 |
Why?
| | Mutation | 1 | 2014 | 3457 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 9342 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6561 | 0.010 |
Why?
| | Aged | 1 | 2013 | 19657 | 0.010 |
Why?
| | Middle Aged | 1 | 2013 | 27617 | 0.010 |
Why?
|
|
Griesinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|